Clinical outcomes of early-stage breast cancer in Morocco: A cohort of 400 women

Table 4 Univariate and multivariate analyses of prognostic factors on overall survival in women with early-stage breast cancer (n = 400)

Factors		Participants	Hazard ratio (univariable)	Hazard ratio (multivariable)
Age (year)	≥ 40	282 (75.2)	-	-
	< 40	93 (24.8)	0.96 (0.56-1.67, P = 0.897)	1.15 (0.65-2.02, P = 0.636)
Grade (SBR)	1-2	268 (71.5)	-	-
	3	107 (28.5)	1.48 (0.90-2.44, P = 0.121)	1.44 (0.85-2.43, P = 0.171)
Histology	IDC	355 (94.7)	-	-
	ILC	20 (5.3)	1.48 (0.59-3.68, P = 0.401)	1.77 (0.69-4.54, P = 0.237)
Hormone receptor	HR-	94 (25.1)	-	-
	HR+	281 (74.9)	0.89 (0.52-1.51, P = 0.660)	0.97 (0.56-1.67, P = 0.903)
pT	pT2-3	111 (29.6)	-	-
	pT1-2	264 (70.4)	0.64 (0.39-1.04, P = 0.071)	1.00 (0.59-1.72, P = 0.988)
pN	pN+	288 (76.8)	-	-
	pN0	87 (23.2)	0.34 (0.16-0.75, P = 0.007)	0.70 (0.27-1.82, P = 0.469)
Stage	3	208 (55.5)	-	-
	1-2	167 (44.5)	0.29 (0.16-0.52, P < 0.001)	0.32 (0.15-0.67, P = 0.002)
Treatment	CMF	142 (37.9)	-	-
	Anthra	233 (62.1)	0.67 (0.42-1.08, P = 0.098)	0.58 (0.35-0.94, P = 0.027)

CMF: Cyclophosphamide, methotrexate, fluorouracil; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; pT: Pathological tumor stage; pN: Pathological lymph node stage; SBR: Scarf-Bloom-Richardson.